TNFRSF11B and osteoporosis: On the other hand, LP45 treatment could dose-dependently reverse, to a large extent, the above serum factors, in the GIO rats (Fig. 2A–D, #P < 0.05, compared to GIO), consistent with a potential anti-osteoporosis property of LP45 that might involve the RANKL/OPG signaling pathway.